Biocon India Group has just formed a new subsidiary, Clinigene, to provide services in clinical trials. Concerns abound, however, as to whether this new subsidiary could prove to be a distraction or worse to this enzyme and pharmaceutical manufacturer.
To illustrate the Indian pharmaceutical and intellectual property environment; and highlight the tradeoffs faced by startups expanding into new sectors.
COULD BE TAUGHT IN THE FOLLOWING COURSE(S)
global entrepreneurship, strategy
*An educator (non-watermarked) copy of this case is available only to individuals who hold teaching positions at academic institutions and want to use the case in a course.